[{"id":"1e1bff7a-1971-43c9-8233-74f128a57b99","acronym":"","url":"https://clinicaltrials.gov/study/NCT05245058","created_at":"2022-02-17T18:22:23.627Z","updated_at":"2025-02-25T13:54:12.974Z","phase":"Phase 1","brief_title":"SPH5030 Tablets in Subjects With Advanced Her2-positive Solid Tumors","source_id_and_acronym":"NCT05245058","lead_sponsor":"Shanghai Pharmaceuticals Holding Co., Ltd","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SPH5030"],"overall_status":"Recruiting","enrollment":" Enrollment 150","initiation":"Initiation: 01/21/2022","start_date":" 01/21/2022","primary_txt":" Primary completion: 12/21/2025","primary_completion_date":" 12/21/2025","study_txt":" Completion: 12/21/2025","study_completion_date":" 12/21/2025","last_update_posted":"2025-02-20"}]